Xarelto rivaroxaban: Phase III started
Bayer began the double-blind, international Phase III EINSTEIN CHOICE trial to compare 10 or 20 mg oral Xarelto once daily for 12 months vs. 100 mg oral acetylsalicylic acid once daily in about 2,850 patients with symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE) who have been treated for 6-12 months with anticoagulation treatment. Bayer markets Xarelto in the EU to prevent atherothrombotic events in combination with standard antiplatelet therapy after acute coronary syndrome (ACS) in adults with elevated cardiac biomarkers, to treat PE and DVT, to prevent VTE in patients undergoing hip or knee replacement surgery, and to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) and recurrent DVT and PE following an acute DVT. ...